Results of the 2-year open postregistration study of Copaxone (glatiramer acetate), conducted in 3 Moscow leading medical centres are given. 32 MS patients with remitting-relapsing MS were investigated in accordance with international requirements (neurological scales, MRI of the brain, multimodal evoked potential). Significant reduction of annual relapse rate for 70.3%, stabilization of neurological status and benign safety profile were demonstrated during Copaxone treatment. Practical recommendations for Copaxone use are given.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
[results open
4
open post-registration
4
post-registration clinical
4
clinical trials
4
copaxone
4
trials copaxone
4
copaxone patients
4
patients multiple
4
multiple sclerosis]
4
sclerosis] 2-year
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!